Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Thorpe

Showing results (121-130 of 137) with videos related to

Pageof 14
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 25, 2025
Outcomes of Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE in Patients with Metastatic Pheochromocytoma and ParagangliomaGokce Belge Bilgin, Brian J Burkett, Cem Bilgin, et al.
EJNMMI Research|March 9, 2026
Predictive value of interim ¹¹C-choline PET/CT for response to radium-223 in metastatic castration-resistant prostate cancerEman E Ahmed, Jack R Andrews, Mohamed E Ahmed, et al.
Biorxiv : the Preprint Server for Biology|July 18, 2023
<i>ent</i> -Verticilide B1 inhibits type 2 ryanodine receptor channels and is antiarrhythmic in Casq2-/- miceAaron Gochman, Tri Q Do, Kyungsoo Kim, et al.
Abdominal Radiology (New York)|June 3, 2025
Localization of PSMA-avid lesions on PSMA PET-CT on prostate MRI in patients with PI-RADS 3Hiroaki Takahashi, Hirotsugu Nakai, Karla V Ballman, et al.
Frontiers in Oncology|July 29, 2024
Performance of ChatGPT-4 and Bard chatbots in responding to common patient questions on prostate cancer <sup>177</sup>Lu-PSMA-617 therapyGokce Belge Bilgin, Cem Bilgin, Daniel S Childs, et al.
Cancer Treatment Reviews|April 16, 2025
Current and future directions in theranostics for neuroendocrine prostate cancerGokce Belge Bilgin, Fabrice Lucien-Matteoni, Aadel A Chaudhuri, et al.
Molecular Pharmacology|January 22, 2024
<i>ent</i>-Verticilide B1 Inhibits Type 2 Ryanodine Receptor Channels and is Antiarrhythmic in <i>Casq2</i> <sup>-/-</sup> MiceAaron Gochman, Tri Q Do, Kyungsoo Kim, et al.
Journal of Neuroinflammation|December 11, 2025
Microglia-derived APOE2 improves remyelination even in the presence of endogenous APOE4Georgia L Nolt, Lesley R Golden, Shealee P Thorpe, et al.
Blood Cancer Journal|August 17, 2023
Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicityWilliam G Breen, Jason R Young, Matthew A Hathcock, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 21, 2025
[<sup>177</sup>Lu] Lu-PSMA-617 treatment for metastatic castration-resistant prostate cancer (mCRPC) with cerebral and cerebellar metastasesGokce Belge Bilgin, Cem Bilgin, Brian J Burkett, et al.
Pageof 14

Showing results (121-130 of 137) with videos related to

Sort By:
Pageof 14
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 25, 2025
Outcomes of Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE in Patients with Metastatic Pheochromocytoma and ParagangliomaGokce Belge Bilgin, Brian J Burkett, Cem Bilgin, et al.
EJNMMI Research|March 9, 2026
Predictive value of interim ¹¹C-choline PET/CT for response to radium-223 in metastatic castration-resistant prostate cancerEman E Ahmed, Jack R Andrews, Mohamed E Ahmed, et al.
Biorxiv : the Preprint Server for Biology|July 18, 2023
<i>ent</i> -Verticilide B1 inhibits type 2 ryanodine receptor channels and is antiarrhythmic in Casq2-/- miceAaron Gochman, Tri Q Do, Kyungsoo Kim, et al.
Abdominal Radiology (New York)|June 3, 2025
Localization of PSMA-avid lesions on PSMA PET-CT on prostate MRI in patients with PI-RADS 3Hiroaki Takahashi, Hirotsugu Nakai, Karla V Ballman, et al.
Frontiers in Oncology|July 29, 2024
Performance of ChatGPT-4 and Bard chatbots in responding to common patient questions on prostate cancer <sup>177</sup>Lu-PSMA-617 therapyGokce Belge Bilgin, Cem Bilgin, Daniel S Childs, et al.
Cancer Treatment Reviews|April 16, 2025
Current and future directions in theranostics for neuroendocrine prostate cancerGokce Belge Bilgin, Fabrice Lucien-Matteoni, Aadel A Chaudhuri, et al.
Molecular Pharmacology|January 22, 2024
<i>ent</i>-Verticilide B1 Inhibits Type 2 Ryanodine Receptor Channels and is Antiarrhythmic in <i>Casq2</i> <sup>-/-</sup> MiceAaron Gochman, Tri Q Do, Kyungsoo Kim, et al.
Journal of Neuroinflammation|December 11, 2025
Microglia-derived APOE2 improves remyelination even in the presence of endogenous APOE4Georgia L Nolt, Lesley R Golden, Shealee P Thorpe, et al.
Blood Cancer Journal|August 17, 2023
Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicityWilliam G Breen, Jason R Young, Matthew A Hathcock, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 21, 2025
[<sup>177</sup>Lu] Lu-PSMA-617 treatment for metastatic castration-resistant prostate cancer (mCRPC) with cerebral and cerebellar metastasesGokce Belge Bilgin, Cem Bilgin, Brian J Burkett, et al.
Pageof 14